Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) EBIT: 2015-2025

Historic EBIT for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$20.2 million.

  • AC Immune's EBIT fell 340.87% to -$20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.4 million, marking a year-over-year decrease of 106.89%. This contributed to the annual value of -$59.8 million for FY2024, which is 1.10% up from last year.
  • According to the latest figures from Q3 2025, AC Immune's EBIT is -$20.2 million, which was up 13.71% from -$23.4 million recorded in Q2 2025.
  • AC Immune's 5-year EBIT high stood at $8.4 million for Q3 2024, and its period low was -$24.7 million during Q4 2021.
  • In the last 3 years, AC Immune's EBIT had a median value of -$20.2 million in 2025 and averaged -$16.7 million.
  • Examining YoY changes over the last 5 years, AC Immune's EBIT showed a top increase of 147.92% in 2024 and a maximum decrease of 432.39% in 2024.
  • AC Immune's EBIT (Quarterly) stood at -$24.7 million in 2021, then rose by 21.47% to -$19.4 million in 2022, then skyrocketed by 79.43% to -$4.0 million in 2023, then slumped by 432.39% to -$21.3 million in 2024, then tumbled by 340.87% to -$20.2 million in 2025.
  • Its EBIT was -$20.2 million in Q3 2025, compared to -$23.4 million in Q2 2025 and -$21.5 million in Q1 2025.